Adverse events (AEs) occurring in >5% of patients during the 52-week clinical study1,2
The majority of diarrhea events were mild and transient, occurred soon after initiation of treatment, and resolved with continued treatment1
Discolored feces (16%)
Discolored feces is expected with an
Incidents were reported during the first
6 months, but diminished over time2
1. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2014. 2. Floege J, Covic AC, Ketteler M, et al; on behalf of the Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037-1046.
Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
For additional important safety information, please see the full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This information is intended for use by US healthcare professionals only.